Crizotinib Current Events

Crizotinib Current Events, Crizotinib News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 3 | 120 Results
First and only therapeutic drug for ALK-positive lung cancer approved
FDA approves the drug crizotinib for use with a subset of lung cancer patients known as ALK-positive -- a (2011-08-31)

ASCO: ALEX trial results show alectinib further outpacing crizotinib in ALK+ NSCLC
Updated data presented at ASCO 2018 further consolidate alectinib as the standard-of-care for first-line treatment of ALK+ non-small cell lung cancer. (2018-06-03)

ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer
Median time to treatment discontinuation (TTD) on crizotinib was 8.8 months; TTD of patients using entrectinib was 14.6 months. Compared with patients on entrectinib, patients on crizotinib had an additional 44 percent chance that their cancer would resume its growth. (2019-05-30)

More evidence for impact of lung cancer targeted therapy from practice-changing trial
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy. (2014-12-04)

Alectinib halts lung cancer growth more than a year longer than crizotinib
Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ALK inhibitor alectinib (Alecensa) halted cancer growth for a median of 15 months longer and caused fewer severe side effects. (2017-06-05)

Crizotinib in bronchial carcinoma: New data not informative
After expiry of the limitation period, the manufacturer presented results from a later data cut-off. Due to frequent treatment switching, these cannot be interpreted in a meaningful way. (2016-10-06)

Ceritinib improves progression-free survival in phase 3 trial of ALK rearranged lung cancer
Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented today at the ESMO 2016 Congress in Copenhagen. (2016-10-09)

Crizotinib reduces tumor size in patients with ALK positive lung cancer
Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. (2012-09-06)

Ceritinib provides longer PFS than chemo in phIII trial of ALK rearranged lung cancer
Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented today at the ESMO 2016 Congress in Copenhagen. (2016-10-09)

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. (2012-09-30)

With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
If the science behind a drug shows it to be rationally targeted at a cancer-causing genetic mutation, and if early clinical trials show the drug is safe and happens to be especially effective, should the drug be held to the same time-consuming and expensive testing standards of traditional chemotherapies? Or is the clinical trials process a relic from the time of earlier, highly toxic therapies? (2013-08-08)

Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'
This study of 65 patients showed that continuing either crizotinib or erlotinib after the treatment of resistant pockets with focused radiation ( (2012-12-01)

Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
A recent University of Colorado Cancer Center case study published in the Journal of Thoracic Oncology describes the never-before-seen case of a patient who tested negative for EML4-ALK fusion based on the well-defined criteria for FISH assay as approved by FDA, but nevertheless experienced remission after treatment with crizotinib. (2012-08-28)

New lung cancer drug shows dramatic results for shrinking tumors
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials. (2010-06-22)

Multicenter study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
A study published this week in the journal Cancer confirms the finding of low-testosterone in crizotinib patients, and for the first time details the mechanism of reduced testosterone, and provides promising preliminary evidence that widely available hormone replacement therapies can alleviate this side effect in many patients. (2013-04-16)

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer
'In 2017, alectinib, another next generation ALK-inhibitor, showed that it was superior to crizotinib in the first-line setting through the ALEX trial and now, in 2018, brigatinib is set to join alectinib as a 1st line option for ALK positive lung cancer,' said D. Ross Camidge, M.D., Ph.D., Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center and the lead author of ALTA-1L. (2018-09-25)

Alectinib potential new standard of care for ALK-positive non-small lung cancer
Results of a 303-patient, multi-national phase III clinical trial known as ALEX published today in the New England Journal of Medicine and presented concurrently at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 argue for alectinib replacing crizotinib as first-line standard of care in advanced ALK-positive non-small cell lung cancer. (2017-06-06)

ALEX study shows alectinib 600 mg more effective than crizotinib in Asian cancer patients
A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress. (2017-11-17)

NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer
In this multi-center study of 50 patients with advanced non-small cell lung cancer testing positive for ROS1 gene rearrangement, the response rate was 72 percent, with 3 complete responses and 33 partial responses. Median progression-free survival was 19.2 months. (2014-09-30)

A novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient
Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog receptor tyrosine kinase (KIT) that can potentially be targeted by KIT inhibitors. (2016-04-11)

Brigatinib first to offer over 1-year control of ALK-positive lung cancer post-crizotinib
Results of a multi-center, 222-person phase 2 clinical trial of the next-generation ALK inhibitor, brigatinib at 180mg/day, used after failure of crizotinib showed a 54 percent response rate and 12.9 month progression-free survival. (2017-05-17)

ASCO18: Updated Phase 1 results of crizotinib against MET-amplified lung cancer
By lowering the bar for 'high MET amplification,' a study suggests that crizotinib may benefit more MET-amplified non-small cell lung cancer patients than previously thought. (2018-06-03)

Crizotinib treatment effective against ROS1-positive lung cancer
Treatment with the targeted therapy drug crizotinib effectively halted the growth of lung tumors driven by rearrangements of the ROS1 gene in a small clinical trial. (2014-09-27)

'Weeding the garden' lets ALK+ lung cancer patients continue crizotinib
Patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. (2014-01-28)

Ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance
Ganetespib killed ALK-driven NSCLC cell lines more effectively than crizotinib. It also displayed greater antitumor activity and prolonged survival in a mouse model. Ganetespib has potential as a new option for treating ALK-dependent lung cancers. (2013-03-26)

Drug resistance biomarker could improve cancer treatment
Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published by Cell Press November 21st in the journal Cell. The study reveals a biomarker that can predict responses to cancer drugs and offers a strategy to treat drug-resistant tumors based on their genetic signature. (2012-11-21)

New crizotinib side-effect
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer appears to reduce kidney function when assessed by one of the most commonly used clinical methods. (2013-11-20)

Study shows different approach after progression in non-small cell lung cancer patients
A new study published in the December 2012 issue of the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology, shows that other approaches to overcome acquired resistance should be considered. (2012-11-15)

Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis
Stage IV ALK+ lung cancer patients treated at UCHealth University of Colorado Hospital between 2009 and 2017 had median overall survival of 6.8 years. (2018-12-31)

New drug may overcome treatment resistance in a high-risk children's cancer
Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma. The 'unparalleled' strength of an ALK inhibitor in their preclinical studies, say the researchers, justifies fast-tracking the drug into pediatric clinical trials this year. (2016-01-06)

New drug successfully treats crizotinib-resistant, ALK-positive lung cancer
Now a new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug. (2014-03-26)

MGH-led studies shed new light on targeted lung cancer therapy
Research teams led by Massachusetts General Hospital Cancer Center investigators are publishing two important studies regarding use of the targeted cancer drug crizotinib for treatment of advanced lung cancer driven by specific genetic mutations. (2013-06-01)

Novel test identifies patients most likely to benefit from ALK inhibition therapy
Researchers have now developed and tested a promising new method for screening anaplastic lymphoma kinase fusions in non-small cell lung carcinoma. This new diagnostic assay offers a cost-effective and easy-to-perform alternative to existing tests. (2012-12-12)

Promising trial of brigatinib shows all next-gen ALK inhibitors may not be created equal
Phase I/II clinical trial results reported at the American Society for Clinical Oncology Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer, with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. Progression-free survival in patients previously treated with crizotinib was 13.4 months. (2015-05-27)

'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine. (2010-10-27)

Brain metastases common and difficult to treat in ROS1 lung cancer
Brain metastases were found to be fairly common in stage IV ROS1-positive cancers and in 47 percent of ROS1 patients, the brain was the first and only site of progression. (2018-07-10)

Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months. (2018-09-24)

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease
A study presented at the American Society of Clinical Oncology Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). (2014-05-31)

Personalizing cancer therapies may combat resistance to targeted therapy drugs
Massachusetts General Hospital physicians report the case of a patients whose lung cancer was re-sensitized to crizotinib, a first-generation targeted therapy drug, by a mutation conferring resistance to a more selective, next-generation ALK inhibitor. (2015-12-23)

Bronchial carcinoma: Added benefit of crizotinib not proven
The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumors are not applicable. (2017-01-11)

Page 1 of 3 | 120 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.